News | December 19, 2025
Ambros Therapeutics launches with $125 million to advance breakthrough therapy for rare pain disorder
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Ryght AI tackles these hurdles with its AI Site Twin platform
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated
